ALLK Allakos Inc
Price (delayed)
$0.326
Market cap
$29.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.3
Enterprise value
$11.65M
Allakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company's lead antibody, lirentelimab
Highlights
Allakos's debt has plunged by 100% from the previous quarter and by 100% YoY
ALLK's EPS is up by 39% year-on-year and by 36% since the previous quarter
The equity has dropped by 53% year-on-year but it has increased by 8% since the previous quarter
The company's quick ratio fell by 22% QoQ and by 2.8% YoY
Key stats
What are the main financial stats of ALLK
Market
Valuations
Earnings
Shares outstanding
90.2M
Market cap
$29.41M
Enterprise value
$11.65M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.37
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$122.23M
Net income
-$115.82M
EBIT
-$122.27M
EBITDA
-$112.52M
Free cash flow
-$93.74M
Per share
Balance sheet
Liquidity
EPS
-$1.3
EPS diluted
-$1.3
Free cash flow per share
-$1.06
Book value per share
$0.88
Revenue per share
$0
TBVPS
$1.09
Total assets
$96.6M
Total liabilities
$17.78M
Debt
$0
Equity
$78.82M
Working capital
$67.8M
Debt to equity
0
Current ratio
4.81
Quick ratio
4.54
Net debt/EBITDA
0.16
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-83.5%
Return on equity
-136.4%
Return on invested capital
-106%
Return on capital employed
-155.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALLK stock price
How has the Allakos stock price performed over time
Intraday
0.93%
1 week
2.13%
1 month
28.4%
1 year
-69.25%
YTD
-73.06%
QTD
43.23%
Financial performance
How have Allakos's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$122.23M
Net income
-$115.82M
Gross margin
N/A
Net margin
N/A
The net income has grown by 38% YoY and by 35% from the previous quarter
The operating income has grown by 38% YoY and by 34% from the previous quarter
Growth
What is Allakos's growth rate over time
Valuation
What is Allakos stock price valuation
P/E
N/A
P/B
0.37
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ALLK's EPS is up by 39% year-on-year and by 36% since the previous quarter
ALLK's price to book (P/B) is 91% less than its 5-year quarterly average of 3.9 and 66% less than its last 4 quarters average of 1.1
The equity has dropped by 53% year-on-year but it has increased by 8% since the previous quarter
Efficiency
How efficient is Allakos business performance
ALLK's return on equity has dropped by 70% year-on-year but it is up by 18% since the previous quarter
The return on assets has declined by 34% year-on-year but it has grown by 18% since the previous quarter
The ROIC has contracted by 27% YoY but it has grown by 18% from the previous quarter
Dividends
What is ALLK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALLK.
Financial health
How did Allakos financials performed over time
Allakos's total liabilities has shrunk by 76% YoY and by 66% QoQ
Allakos's total assets has plunged by 60% YoY and by 22% from the previous quarter
Allakos's debt is 100% less than its equity
Allakos's debt has plunged by 100% from the previous quarter and by 100% YoY
ALLK's debt to equity has plunged by 100% from the previous quarter and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.